Navigation Links
Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
Date:4/30/2009

n will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss first quarter 2009 results, the outlook for 2009 and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 96139762. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Daylight Time, May 15, 2009. To access the live webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from it
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Annapolis, MD (PRWEB) , ... July 07, 2015 ... ... quality and an official accrediting body as designated by the Centers for Medicare ... improved user experience and to enhance compatibility with mobile devices. , The most ...
(Date:7/7/2015)... MO (PRWEB) , ... July 07, 2015 , ... ... liability law announce the launch of their new website, the Invokana Ketoacidosis ... Invokana FDA warning*, and serves as a resource for persons wishing to learn ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
(Date:7/7/2015)... ... 07, 2015 , ... CareSync proudly announces today that Amy ... White House as a “Champion of Change” for Precision Medicine on Wednesday, July ... of Change program recognizes Gleason and eight other extraordinary individuals who are making ...
(Date:7/7/2015)... ... July 07, 2015 , ... Each year the ... charitable organizations on a local, national and international level; however, the Holiday Inn now ... will have a high impact on the beneficiaries. In September of 2014 they hosted ...
Breaking Medicine News(10 mins):Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3
... Aon Benfield, the world,s premier ... preliminary forecast of direct insured losses resulting from ... http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO )"While the maximum potential exposed insurance limits ... range of direct insured losses will be a ...
... Blue Foundation for a Healthy Florida , the philanthropic ... (BCBSF), has approved $761,000 in grants to be awarded ... services to in-need Floridians."Around 20 percent of Florida residents ... Blue Foundation for a Healthy Florida. "That,s more than ...
... RIVER EDGE, N.J., Jan. 14 Nephros, Inc. ... company developing and marketing filtration products for therapeutic ... that it has received notice from the NYSE ... or "AMEX" or the "Exchange"), regarding AMEX,s intention ...
... drugs in some cases , , WEDNESDAY, Jan. 14 (HealthDay News) ... antipsychotic drugs, used to treat conditions ranging from schizophrenia to ... to cardiac arrest. , The odds of a heart ... appropriate for certain patients. Still, doctors, families and patients should ...
... Jan. 14 The National Council of Legislators ... comprised of lawmakers from states with casinos and ... resolution Saturday encouraging states to take ... was adopted at the NCLGS 2009 Winter Meeting, ...
... January 14, 2009 - A new study suggests ... in the construction of artificial skin. The findings mark ... to pioneer a method of organ reconstruction. The study ... of the International Federation for Artificial Organs (IFAO), the ...
Cached Medicine News:Health News:Aon Benfield Forecasts Potential Impact on the Insurance Industry Resulting From the Alleged Madoff Scandal 2Health News:Florida's Uninsured and Underinsured to Benefit from Statewide Grants 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 3Health News:Nephros Receives Notice of Intention to Delist from AMEX 4Health News:Newer Antipsychotics Pose Cardiac Risk: Study 2Health News:National Council of Legislators From Gaming States Adopts Resolution Supporting 100% Smokefree Gaming Venues 2Health News:Study uses bone marrow stem cells to regenerate skin 2
(Date:7/7/2015)... Ill. , July 7, 2015  Monopar Therapeutics ... oncology compounds, announced that its co-founder and CEO, ... British Council,s Education U.K. Alumni Entrepreneurial Award. The British ... China , India , and ... recognizes outstanding achievements made by entrepreneurs who have leveraged ...
(Date:7/7/2015)... SAN DIEGO , July 7, 2015 /PRNewswire/ ... pharmaceuticals, announced today initiation of enrollment and dosing ... clinical study of ABX-1431, a first-in-class, investigational endocannabinoid ... technology platform, which finds new small molecule drug ... of enzymes with important regulatory roles in human ...
(Date:7/7/2015)... NEW YORK , July 7, 2015  New ... treated with radiation therapy versus surgery for prostate ... University of Toronto presented their findings at the ... last month, which further suggest that prostate ... increased risk of requiring minimally invasive urologic procedures due ...
Breaking Medicine Technology:Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 2New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 3New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 4
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, today announced shareholder resolutions adopted at ... Kong on December 22, 2010. At the ... Ms. Joyce I-Yin Hsu and Mr. Wu Qiyao, each ...
... Inc. (Nasdaq: CEPH ) today announced that ... the U.S. Food and Drug Administration (FDA) for the ... [C-IV] for the treatment of patients with excessive sleepiness ...  In its letter to the company, the FDA reiterated ...
Cached Medicine Technology:Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 2Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 3
... Titer Performance Panel consists of plasma specimens ... positive for antibodies to HTLV I and ... by manufacturers and diagnostic laboratories to evaluate ... all major test systems are included for ...
... Avaulta™ BioSynthetic Mesh is ... coated in the central ... hydrophilic film of porcine ... of the Avaulta™ BioSynthetic ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
... Bard® Dermal Allograft ... of most pelvic floor ... highly resistant to suture ... and serves as a ...
Medicine Products: